Literature DB >> 26686809

Diversity and combinations of infectious agents in 38 adults with an infection-triggered reactive haemophagocytic syndrome: a multicenter study.

N Lerolle1, M Laanani2, S Rivière3, L Galicier4, P Coppo5, J-L Meynard6, J-M Molina7, E Azoulay8, C Aumont9, C Marzac10, L Fardet11, O Lambotte12.   

Abstract

Reactive haemophagocytic syndrome (HS) is a rare condition that occurs in patients with infections, haematological malignancies or autoimmune diseases. Although various microorganisms are thought to trigger HS, most of the literature data on this topic have been gathered in single-centre case series. Here, we sought to characterize infectious triggers in a large, multicentre cohort of patients with HS. Patients were included in the present study if HS was solely due to one or more infections. Detailed microbiological data were recorded. Of the 162 patients with HS in the cohort, 40 (25%) had at least one infection and 38 of the latter (including 14 women, 36.8%) were included. The median age was 46 years. Seven patients were presumed to be immunocompetent (18.4%), whereas 19 patients (50%) were infected with human immunodeficiency virus and 12 patients (31.6%) were immunocompromised for other reasons. Twenty-seven patients (71.1%) had a single infection, whereas six (15.8%) and five (13.1%) patients had, respectively, two and three concomitant infections. We observed pyogenic bacterial infections (n = 7), tuberculosis (n = 10), non-tuberculous mycobacteriosis (n = 3), viral infections (n = 17: 11 cytomegalovirus, three Epstein-Barr virus, two human herpesvirus 8, one herpes simplex virus 2), parasitic infections (n = 8: four disseminated toxoplasmosis, one leishmaniasis, three malaria), fungal infections (n = 5: four pulmonary pneumocystosis and one candidaemia). Eighteen patients (47.4%) received corticosteroids and/or etoposide. Twelve patients died (31.6%). All multiple infections and all deaths occurred in immunocompromised patients. When compared with patients suffering from malignancy-associated HS, patients with infection-triggered HS were younger and more likely to be immunocompromised, and had a better outcome.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Human immunodeficiency virus; immunodepression; infection; reactive haemophagocytic syndrome; tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26686809     DOI: 10.1016/j.cmi.2015.11.018

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  10 in total

1.  Tuberculosis-associated hemophagocytic lymphohistiocytosis with subsequent unmasking cryptococcal immune reconstitution inflammatory syndrome (IRIS) in an HIV-negative man.

Authors:  Hilte F Geerdes-Fenge; Micha Löbermann; Christoph J Hemmer; Orsolya Benedek; Emil C Reisinger
Journal:  Infection       Date:  2018-09-26       Impact factor: 3.553

2.  Clinical Characteristics of Adult Hemophagocytic Lymphohistiocytosis in the Emergency Department.

Authors:  Fang-Jie Zhang; Guo-Qing Huang; Jia Li; Ji Xu; Xiang-Min Li; Ai-Min Wang
Journal:  Int J Gen Med       Date:  2021-08-20

Review 3.  Hemophagocytic lymphohistiocytosis diagnosed by bone marrow trephine biopsy in living post-COVID-19 patients: case report and mini-review.

Authors:  Maria Ioannou; Konstantina Zacharouli; Sotirios G Doukas; Michael D Diamantidis; Vaya Tsangari; Konstantinos Karakousis; George K Koukoulis; Dimitra P Vageli
Journal:  J Mol Histol       Date:  2022-06-14       Impact factor: 3.156

4.  Cholestatic jaundice: a unique presentation leading to the diagnosis of HLH with Hodgkin lymphoma, HIV and EBV.

Authors:  Hira Shaikh; Soorih Shaikh; Amir Kamran; Prerna Mewawalla
Journal:  BMJ Case Rep       Date:  2018-05-12

5.  Hemophagocytic syndrome in patients infected with the human immunodeficiency virus: A study of 15 consecutive patients.

Authors:  L Suárez-Hormiga; M N Jaén-Sánchez; E A Verdugo-Espinosa; C Carranza-Rodríguez; P M Hernández-Cabrera; E Pisos-Álamo; A Francés-Urmeneta; J L Pérez-Arellano
Journal:  Rev Esp Quimioter       Date:  2020-06-19       Impact factor: 1.553

Review 6.  Hemophagocytic Lymphohistiocytosis and Infection: A Literature Review.

Authors:  Evgenia Koumadoraki; Nikolaos Madouros; Shayka Sharif; Amber Saleem; Sommer Jarvis; Safeera Khan
Journal:  Cureus       Date:  2022-02-20

Review 7.  COVID-19 Clinical Presentation Among HIV-Infected Persons in China: A Systematic Review.

Authors:  Dayong Huang; Jiawulan Zunong; Menglong Li; Dan Li; JiaJian Gong; Sten H Vermund; Yifei Hu
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-08       Impact factor: 5.495

8.  Disseminated Tuberculosis Associated Hemophagocytic Lymphohistiocytosis in a Pregnant Woman With Evans syndrome: A Case Report and Literature Review.

Authors:  Yun-Feng Shi; Xiao-Han Shi; Yuan Zhang; Jun-Xian Chen; Wen-Xing Lai; Jin-Mei Luo; Jun-Hui Ba; Yan-Hong Wang; Jian-Ning Chen; Ben-Quan Wu
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

9.  Hemophagocytic Lymphohistiocytosis Following Skin and Soft Tissue Infection in a Patient With Human Immunodeficiency Virus.

Authors:  Omid Yazdanpanah; Lea M Monday; Asra N Shaik; Zachary Cantor; Jie Chi
Journal:  Cureus       Date:  2021-06-16

10.  Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

Authors:  Pilar Brito-Zerón; Belchin Kostov; Pedro Moral-Moral; Aleida Martínez-Zapico; Carmen Díaz-Pedroche; Guadalupe Fraile; Patricia Pérez-Guerrero; Eva Fonseca; Angel Robles; María P Vaquero-Herrero; María Andrés Calvo; María José Forner; Cesar Morcillo; José Larrañaga; Monica Rodriguez-Carballeira; Manuel Ruiz-Muñoz; Robert Hurtado-García; Sergio Prieto-González; Asun Aljibe Aguilar; Luis Caminal-Montero; Pilar Hernández-Jiménez; Cristina Rodríguez Fernández-Viagas; Pedro Castro; Victoria Morell Massó; Alejandra Flores-Chavez; Manuel Ramos-Casals
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.